Skip to main content
CKDXF logo

Ceryvyn Therapeutics Limited (CKDXF) Stock Price & Analysis

Ceryvyn Therapeutics Limited (CKDXF) — price $0.0107 (0.00%), as of the Nov 19, 2026 trading session; market cap $14.6M.

Educational signal · not a buy or sell recommendation · How to read this

$0.0107 $0.00 (0.00%) Market Cap $14.6M

Ceryvyn Therapeutics Limited · CKDXF

Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing therapies for eye diseases.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0107
Change on the day0.00%
Market capitalisation$14.6M
Shares traded on the day130

Price & events

Other perspectives

Council score for Ceryvyn Therapeutics (CKDXF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Apr 30, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 30, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ceryvyn Therapeutics (CKDXF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ceryvyn Therapeutics Limited (CKDXF) is the company analyzed here. In Q2 FY2026 it reported revenue of $667.25 and net income of $227M. The market values it at $14.6M.

2 · Latest results

What do the latest results show for Ceryvyn Therapeutics (CKDXF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $667.25. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$667.25$227M$0.17 (diluted)
Q4 FY2025$2,538-$32M-$0.03 (diluted)
Q2 FY2025$23,964-$123M-$0.19 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ceryvyn Therapeutics (CKDXF)?

Short answer · as of

The distress and quality screens read Altman Z -25.27 · Piotroski F 4.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -25.27 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CKDXF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CKDXF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About CKDXF

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

Is CKDXF a good stock to buy?

Stock Expert AI does not rate CKDXF buy, sell or hold. Ceryvyn Therapeutics Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CKDXF stock price today?

The last price recorded for Ceryvyn Therapeutics Limited (CKDXF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for CKDXF?

Evaluate CKDXF on fundamentals, analyst consensus, and risk factors. Not financial advice.

How frequently does CKDXF data refresh on this page?

CKDXF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CKDXF's recent stock price performance?

Ceryvyn Therapeutics Limited (CKDXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CKDXF overvalued or undervalued right now?

Ceryvyn Therapeutics Limited (CKDXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CKDXF before investing?

Before investing in Ceryvyn Therapeutics Limited (CKDXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding CKDXF to a portfolio?

No dossier-level strength is on record for Ceryvyn Therapeutics Limited (CKDXF) yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 10 figures on this page — 8 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.